BioVie Inc. (BIVI): Price and Financial Metrics

BioVie Inc. (BIVI): $0.45

0.01 (-1.26%)

POWR Rating

Component Grades








Add BIVI to Watchlist
Sign Up

Industry: Biotech




#215 of 359

in industry

BIVI Price/Volume Stats

Current price $0.45 52-week high $6.74
Prev. close $0.46 52-week low $0.44
Day low $0.44 Volume 857,900
Day high $0.47 Avg. volume 1,767,693
50-day MA $0.51 Dividend yield N/A
200-day MA $1.96 Market Cap 27.71M

BIVI Stock Price Chart Interactive Chart >

BioVie Inc. (BIVI) Company Bio

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.

BIVI Latest News Stream

Event/Time News Detail
Loading, please wait...

BIVI Latest Social Stream

Loading social stream, please wait...

View Full BIVI Social Stream

Latest BIVI News From Around the Web

Below are the latest news stories about BIOVIE INC that investors may wish to consider to help them evaluate BIVI as an investment opportunity.

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / December 22, 2023 / RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December ...

Yahoo | December 22, 2023

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | December 11, 2023

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Yahoo | December 1, 2023

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Yahoo | November 30, 2023

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

Yahoo | November 30, 2023

Read More 'BIVI' Stories Here

BIVI Price Returns

1-mo -7.18%
3-mo -64.00%
6-mo -75.00%
1-year N/A
3-year -96.73%
5-year -96.40%
YTD -64.29%
2023 -83.78%
2022 72.67%
2021 -74.02%
2020 394.86%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!